PT - JOURNAL ARTICLE AU - Ghafari, Mahan AU - Kemp, Steven A. AU - Hall, Matthew AU - Clarke, Joe AU - Ferretti, Luca AU - Thomson, Laura AU - Studley, Ruth AU - Rourke, Emma AU - COVID-19 Infection Survey Group AU - The COVID-19 Genomics UK (COG-UK) Consortium AU - Walker, Ann Sarah AU - Golubchik, Tanya AU - Lythgoe, Katrina TI - Determinants of SARS-CoV-2 within-host evolutionary rates in persistently infected individuals AID - 10.1101/2024.06.21.24309297 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.21.24309297 4099 - http://medrxiv.org/content/early/2024/06/22/2024.06.21.24309297.short 4100 - http://medrxiv.org/content/early/2024/06/22/2024.06.21.24309297.full AB - Understanding the within-host evolutionary dynamics of SARS-CoV-2, particularly in relation to variant emergence, is crucial for public health. From a community surveillance study, we identified 576 persistent infections, more common among males and those over 60. Our findings show significant variation in evolutionary rates among individuals, driven by nonsynonymous mutations. Longer-lasting infections accumulated mutations faster, with no link to demographics, vaccination status, virus lineage, or prior infection. The nonsynonymous rate was particularly high within the N-terminal and receptor binding domains of Spike. ORF6 was under strong purifying selection, making it a potential therapeutic target. We also identified 379 recurring mutations, with half having a negative fitness effect and very low prevalence at the between-host level, indicating some mutations are favoured during infection but disadvantageous for transmission. Our study highlights the highly heterogenous nature of within-host evolution of SARS-CoV-2 which may in turn help inform future intervention strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe CIS was funded by the Department of Health and Social Care and the UK Health Security Agency, with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. The COVID-19 Infection Survey Group of the COVID-19 Genomics UK (COG-UK) Consortium was supported by funding from the Medical Research Council part of UK Research & Innovation, the National Institute of Health Research (NIHR) (grant code: MC_PC_19027) and Genome Research Limited, operating as the Wellcome Sanger Institute. We acknowledge use of data generated through the COVID-19 Genomics Programme funded by the Department of Health and Social Care. A.S.W. is supported by the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with the UK Health Security Agency (NIHR200915) and the NIHR Oxford Biomedical Research Centre, and is an NIHR Senior Investigator. K.L. is supported by the Royal Society and the Wellcome Trust (107652/Z/15/Z) and by the Li Ka Shing Foundation. The research was supported by the Wellcome Trust Core Award grant number 203141/Z/16/Z, with funding from the NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health, the Department of Health and Social Care or the UK Health Security Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll raw consensus sequences have been made publicly available as part of the COG-UK Consortium (https://webarchive.nationalarchives.gov.uk/ukgwa/20230505214946/https://www.cogconsortium.uk/priority-areas/data-linkage-analysis/) and are available from the European Nucleotide Archive at EMBL-EBI under accession number PRJEB37886.